Therefore, downregulation of Smad4, or treatment with inhibitors to inhibit TGFβ signaling or Smad2 and/or Smad3 phosphorylation, combined with Dox may be a potential novel strategy with which to treat colon cancer. Here, SMAD2 is linked to malignant colon neoplasm.